MARKET

VRCA

VRCA

Verrica Pharmaceuticals
NASDAQ
5.74
-0.30
-4.89%
Opening 15:37 02/11 EST
OPEN
6.09
PREV CLOSE
6.03
HIGH
6.09
LOW
5.67
VOLUME
131.68K
TURNOVER
--
52 WEEK HIGH
9.82
52 WEEK LOW
3.280
MARKET CAP
91.70M
P/E (TTM)
-1.6686
1D
5D
1M
3M
1Y
5Y
1D
Verrica Pharmaceuticals Launches Ycanth for treatment of Molluscum in Japan
TipRanks · 2d ago
Verrica Pharma Announces Launch Of YCANTH In Japan By Its Partner, Torii Pharma, For Treatment Of Molluscum Contagiosum
Benzinga · 2d ago
Verrica Pharmaceuticals Launches YCANTH in Japan with Torii Pharmaceutical
Reuters · 2d ago
VERRICA PHARMACEUTICALS ANNOUNCES LAUNCH OF YCANTH® FOR THE TREATMENT OF MOLLUSCUM CONTAGIOSUM IN JAPAN BY PARTNER TORII PHARMACEUTICAL
Reuters · 2d ago
Weekly Report: what happened at VRCA last week (0202-0206)?
Weekly Report · 2d ago
New Strong Buy Stocks for February 2nd
NASDAQ · 02/02 10:59
Weekly Report: what happened at VRCA last week (0126-0130)?
Weekly Report · 02/02 09:23
Verrica Pharmaceuticals Files Initial Beneficial Ownership Statement for BKB Growth Investments
Reuters · 01/26 21:24
More
About VRCA
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).

Webull offers Verrica Pharmaceuticals Inc stock information, including NASDAQ: VRCA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRCA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VRCA stock methods without spending real money on the virtual paper trading platform.